Bone health management in prostate cancer patients receiving androgen deprivation therapy

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 1, 2012, Pages 84-90

  Dhanapal, Vishnuprabha ^a   Reeves, David J ^b  

^a HENRY FORD HOSPITAL   (United States)

^b BUTLER UNIVERSITY   (United States)

Author keywords

Androgen deprivation therapy; osteoporosis; prostate cancer

Indexed keywords

ANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DEGARELIX; FLUTAMIDE; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; MEGESTROL; NILUTAMIDE; TRIPTORELIN; VITAMIN D;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; CANCER PATIENT; DUAL ENERGY X RAY ABSORPTIOMETRY; EXTERNAL BEAM RADIOTHERAPY; FRACTURE; HEALTH CARE MANAGEMENT; HIP FRACTURE; HOT FLUSH; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; REVIEW; RISK; RISK ASSESSMENT; RISK FACTOR; SEXUAL DYSFUNCTION; VITAMIN SUPPLEMENTATION;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; CALCIUM; FRACTURES, BONE; GONADOTROPIN-RELEASING HORMONE; GUIDELINE ADHERENCE; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; VITAMIN D;

EID: 84857957486     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155211402105     Document Type: Review

References (32)

1. Jemel A, Siegel R, Ward E, et al. Cancer Statistics. Ca Cancer J Clin. 2009 ; 59: 225-249
2. American Cancer Society. What are the key statistics about prostate cancer?2010, http://www.cancer.org/docroot/cri/content/cri-2-4-1x-what-are-the- key-statistics-for-prostate-cancer-36.asp (accessed 15 January 2011).
3. Fowler JE, Bigler SA, White PC, et al. Hormone therapy for locally advanced prostate cancer. J Urol. 2002 ; 168: 546-549 (Pubitemid 34793291)
4. Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med. 2008 ; 358: 1474-1482
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Prostate Cancer. V.1.2010. Fort Washington, PA: National Comprehensive Cancer Network; 2010. http://www.nccn.org/professionals/physician- gls/PDF/prostate.pdf (accessed 15 February 2010).
6. Wiren K, Orwoll E Osteoporosis in Men. Orwoll E, ed. San Diego: Academic Press ; 1999: 211-274.
7. Higano CS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol. 2003 ; 21: 392-398 (Pubitemid 38534183)
8. Baillie SP, Davison CE, Johnson FJ, et al. Pathogenesis of vertebral crush fractures in men. Age Ageing. 1992 ; 21: 139-141
9. Jackson JA, Spiekerman AM. Testosterone deficiency is common in men with hip fracture after simple falls. Clin Res. 1989 ; 37: 131-136
10. World Health Organization. Fracture Risk Assessment Tool. http://www.sheffield.ac.uk/FRAX/ (accessed January 2010).
11. National osteoporosis foundation. The clinician's guide to prevention and treatment of osteoporosis. http://www.nof.org/professionals/pdfs/NOF- ClinicianGuide2009-v7.pdf (accessed January 2010).
12. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really now?. Nat Clin Pract Urol. 2008 ; 5 (1). 24-34
13. Orsini LS, Rousculp MD, Long SR, et al. Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int. 2005 ; 16 (4). 359-371 (Pubitemid 40487393)
14. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999 ; 353 (9156). 878-882 (Pubitemid 29126875)
15. Saad F, Gleason DM, Murray R, et al. Zoledronic acid prostate cancer study group: a randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. JNatl Cancer Inst. 2002 ; 94: 1458-1468
16. Ryan CW, Huo D, Stallings JW, et al. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology. 2007 ; 70 (1). 122-126 (Pubitemid 47081101)
17. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001 ; 345 (13). 948-955
18. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003 ; 169 (6). 2008-2012 (Pubitemid 36576705)
19. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007 ; 25 (9). 1038-1042 (Pubitemid 46596753)
20. American Cancer Society. Cancer Facts and Figures2010www.cancer.org/ downloads/STT/Cancer-Facts-and-Figures-2010.pdf (accessed March 2010).
21. Tanvetyanon T. Physician practices of bone density testing and drugprescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005 ; 103: 237-241 (Pubitemid 40129281)
22. Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004 ; 100: 892-899 (Pubitemid 38222847)
23. Shahinian VB, Kuo Y-F, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005 ; 352: 154-164 (Pubitemid 40096612)
24. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005 ; 90: 6410-6417 (Pubitemid 41759293)
25. Bolla M, Theodordeus M, de Reijke, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009 ; 360: 2516-2527
26. Horwitz EM, Bae KY, Hanks GE, et al. Ten-year follow-up of RTOG 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 ; 26 (15). 2497-2504
27. Souhami L, Bae K, Pilepich M, et al. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol. 2009 ; 27: 2137-2143
28. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med. 1997 ; 337: 670-676 (Pubitemid 27375473)
29. Trivedi DP, Doll R, Tee Khaw K. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. BMJ. 2002 ; 326: 469-469
30. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss inmen receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003 ; 169: 2008-2012 (Pubitemid 36576705)
31. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005 ; 16: 581-589 (Pubitemid 40897454)
32. Wilcox A, Carnes ML, Moon TD, et al. Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother. 2006 ; 40: 2107-2114 (Pubitemid 44954427)